HRP20141150T1 - Kombinacijska terapija raka sa hsp90 inhibitornim spojevima - Google Patents
Kombinacijska terapija raka sa hsp90 inhibitornim spojevima Download PDFInfo
- Publication number
- HRP20141150T1 HRP20141150T1 HRP20141150AT HRP20141150T HRP20141150T1 HR P20141150 T1 HRP20141150 T1 HR P20141150T1 HR P20141150A T HRP20141150A T HR P20141150AT HR P20141150 T HRP20141150 T HR P20141150T HR P20141150 T1 HRP20141150 T1 HR P20141150T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- hydroxy
- cancer
- tautomer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27933009P | 2009-10-19 | 2009-10-19 | |
| US33577810P | 2010-01-11 | 2010-01-11 | |
| EP10768357.5A EP2490688B1 (en) | 2009-10-19 | 2010-10-19 | Combination cancer therapy with hsp90 inhibitory compounds |
| PCT/US2010/053199 WO2011049946A1 (en) | 2009-10-19 | 2010-10-19 | Combination cancer therapy with hsp90 inhibitory compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20141150T1 true HRP20141150T1 (hr) | 2015-01-30 |
Family
ID=43218142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141150AT HRP20141150T1 (hr) | 2009-10-19 | 2010-10-19 | Kombinacijska terapija raka sa hsp90 inhibitornim spojevima |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20120245186A1 (enExample) |
| EP (1) | EP2490688B1 (enExample) |
| JP (2) | JP2013508378A (enExample) |
| KR (1) | KR20120093970A (enExample) |
| CN (1) | CN102695504A (enExample) |
| AU (1) | AU2010308306A1 (enExample) |
| BR (1) | BR112012009215A2 (enExample) |
| CA (1) | CA2779233A1 (enExample) |
| CY (1) | CY1115902T1 (enExample) |
| DK (1) | DK2490688T3 (enExample) |
| EA (1) | EA022119B1 (enExample) |
| ES (1) | ES2526566T3 (enExample) |
| HR (1) | HRP20141150T1 (enExample) |
| MX (1) | MX2012004577A (enExample) |
| NZ (2) | NZ599445A (enExample) |
| PH (1) | PH12012500748A1 (enExample) |
| PL (1) | PL2490688T3 (enExample) |
| PT (1) | PT2490688E (enExample) |
| RS (1) | RS53716B1 (enExample) |
| SI (1) | SI2490688T1 (enExample) |
| WO (1) | WO2011049946A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1934185A1 (en) | 2005-08-12 | 2008-06-25 | Synta Pharmaceuticals Corporation | Pyrazole compounds that modulate hsp90 activity |
| US20070250391A1 (en) * | 2006-04-05 | 2007-10-25 | Prade Hendrik D | Merchandising system and method for food and non-food items for a meal kit |
| CA2653329C (en) | 2006-05-25 | 2018-01-16 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| CA2653336C (en) | 2006-05-25 | 2014-10-28 | Synta Pharmaceuticals Corp. | Method for treating non-hodgkin's lymphoma |
| CA2653217A1 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
| US9156836B2 (en) * | 2008-05-16 | 2015-10-13 | Synta Pharmaceuticals Corp. | Tricyclic triazole compounds that modulate HSP90 activity |
| US8450500B2 (en) | 2008-06-04 | 2013-05-28 | Synta Pharmaceuticals Corp. | Pyrrole compounds that modulate HSP90 activity |
| PL2328893T3 (pl) * | 2008-08-08 | 2013-09-30 | Synta Pharmaceuticals Corp | Związki triazolowe modulujące aktywność Hsp90 |
| TW201011003A (en) | 2008-08-08 | 2010-03-16 | Synta Pharmaceuticals Corp | Triazole compounds that modulate HSP90 activity |
| KR20120117905A (ko) | 2010-01-28 | 2012-10-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 프로테아좀 활성을 향상시키는 조성물 및 방법 |
| WO2011133520A1 (en) | 2010-04-19 | 2011-10-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| AU2011255438A1 (en) * | 2010-05-20 | 2013-01-10 | Synta Pharmaceuticals Corp. | Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds |
| WO2011146801A1 (en) * | 2010-05-20 | 2011-11-24 | Synta Pharmaceuticals Corp. | Formulation and dosing of hsp90 inhibitory compounds |
| US20130171105A1 (en) * | 2010-05-24 | 2013-07-04 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor |
| EP2616063A1 (en) * | 2010-09-13 | 2013-07-24 | Synta Pharmaceuticals Corp. | Hsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients |
| EP3552664A1 (en) | 2011-05-12 | 2019-10-16 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
| US20140228418A1 (en) * | 2011-05-23 | 2014-08-14 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mek inhibitors |
| US20140315943A1 (en) * | 2011-05-24 | 2014-10-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors |
| US20140194388A1 (en) * | 2011-05-26 | 2014-07-10 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with chk inhibitors |
| JP2014520808A (ja) | 2011-07-07 | 2014-08-25 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０阻害化合物を用いた癌の治療 |
| CA2853806C (en) | 2011-11-02 | 2020-07-14 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
| WO2013067162A1 (en) * | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| CA2854188A1 (en) * | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| US9849135B2 (en) | 2013-01-25 | 2017-12-26 | President And Fellows Of Harvard College | USP14 inhibitors for treating or preventing viral infections |
| CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
| WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| JP6624594B2 (ja) | 2014-08-04 | 2019-12-25 | ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ | 炎症性、代謝性、腫瘍性および自己免疫疾患の処置に有用なピリミジンの任意選択により縮合されているヘテロシクリル置換誘導体 |
| JP2018523665A (ja) | 2015-08-06 | 2018-08-23 | キメリックス インコーポレイテッド | 抗ウイルス剤として有用なピロロピリミジンヌクレオシドおよびその類縁体 |
| CN105237533B (zh) * | 2015-10-26 | 2017-03-22 | 中国药科大学 | 四氢吡啶并[4,3‑d]嘧啶类Hsp90抑制剂及其医药用途 |
| WO2019060692A1 (en) | 2017-09-21 | 2019-03-28 | Chimerix, Inc. | MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES |
| WO2021124277A1 (en) | 2019-12-20 | 2021-06-24 | Nuevolution A/S | Compounds active towards nuclear receptors |
| US11685727B2 (en) | 2019-12-20 | 2023-06-27 | Nuevolution A/S | Compounds active towards nuclear receptors |
| CA3174252A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
| EP4126875A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| KR20140006070A (ko) | 2004-11-18 | 2014-01-15 | 신타 파마슈티칼스 코프. | Ｈｓｐ90 활성을 조절하는 트리아졸 화합물 |
| CA2653217A1 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
| DE102007002715A1 (de) * | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Triazolderivat |
| JPWO2008108386A1 (ja) * | 2007-03-05 | 2010-06-17 | 協和発酵キリン株式会社 | 医薬組成物 |
| WO2009002321A1 (en) | 2007-06-27 | 2008-12-31 | Thomson Licensing | Enhancing image quality |
| CN101801983B (zh) * | 2007-08-13 | 2014-01-29 | 辛塔制药公司 | 调控hsp90活性的三唑化合物 |
| JP2014520808A (ja) * | 2011-07-07 | 2014-08-25 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０阻害化合物を用いた癌の治療 |
-
2010
- 2010-10-19 NZ NZ599445A patent/NZ599445A/en not_active IP Right Cessation
- 2010-10-19 RS RS20140705A patent/RS53716B1/sr unknown
- 2010-10-19 CA CA2779233A patent/CA2779233A1/en not_active Abandoned
- 2010-10-19 DK DK10768357.5T patent/DK2490688T3/en active
- 2010-10-19 AU AU2010308306A patent/AU2010308306A1/en not_active Abandoned
- 2010-10-19 KR KR1020127012977A patent/KR20120093970A/ko not_active Ceased
- 2010-10-19 PL PL10768357T patent/PL2490688T3/pl unknown
- 2010-10-19 PT PT107683575T patent/PT2490688E/pt unknown
- 2010-10-19 BR BR112012009215A patent/BR112012009215A2/pt not_active IP Right Cessation
- 2010-10-19 CN CN201080056689XA patent/CN102695504A/zh active Pending
- 2010-10-19 ES ES10768357.5T patent/ES2526566T3/es active Active
- 2010-10-19 SI SI201030832T patent/SI2490688T1/sl unknown
- 2010-10-19 EP EP10768357.5A patent/EP2490688B1/en active Active
- 2010-10-19 WO PCT/US2010/053199 patent/WO2011049946A1/en not_active Ceased
- 2010-10-19 JP JP2012535301A patent/JP2013508378A/ja not_active Ceased
- 2010-10-19 US US13/501,608 patent/US20120245186A1/en not_active Abandoned
- 2010-10-19 NZ NZ622713A patent/NZ622713A/en not_active IP Right Cessation
- 2010-10-19 PH PH1/2012/500748A patent/PH12012500748A1/en unknown
- 2010-10-19 EA EA201270570A patent/EA022119B1/ru not_active IP Right Cessation
- 2010-10-19 HR HRP20141150AT patent/HRP20141150T1/hr unknown
- 2010-10-19 MX MX2012004577A patent/MX2012004577A/es active IP Right Grant
-
2014
- 2014-12-31 CY CY20141101097T patent/CY1115902T1/el unknown
-
2015
- 2015-10-08 JP JP2015199844A patent/JP2016041715A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA201270570A1 (ru) | 2012-09-28 |
| RS53716B1 (sr) | 2015-04-30 |
| US20120245186A1 (en) | 2012-09-27 |
| HK1175112A1 (en) | 2013-06-28 |
| NZ622713A (en) | 2015-07-31 |
| PT2490688E (pt) | 2014-12-29 |
| CN102695504A (zh) | 2012-09-26 |
| ES2526566T3 (es) | 2015-01-13 |
| SI2490688T1 (sl) | 2015-01-30 |
| NZ599445A (en) | 2014-04-30 |
| EP2490688B1 (en) | 2014-10-08 |
| WO2011049946A1 (en) | 2011-04-28 |
| DK2490688T3 (en) | 2014-12-08 |
| AU2010308306A1 (en) | 2012-05-10 |
| CY1115902T1 (el) | 2017-01-25 |
| BR112012009215A2 (pt) | 2019-09-24 |
| EA022119B1 (ru) | 2015-11-30 |
| MX2012004577A (es) | 2012-06-13 |
| CA2779233A1 (en) | 2011-04-28 |
| EP2490688A1 (en) | 2012-08-29 |
| JP2016041715A (ja) | 2016-03-31 |
| PH12012500748A1 (en) | 2012-10-29 |
| KR20120093970A (ko) | 2012-08-23 |
| JP2013508378A (ja) | 2013-03-07 |
| PL2490688T3 (pl) | 2015-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20141150T1 (hr) | Kombinacijska terapija raka sa hsp90 inhibitornim spojevima | |
| NZ595035A (en) | Substituted diazole and triazole compounds and compositions and methods of use | |
| US20130156755A1 (en) | Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor | |
| US20130171105A1 (en) | Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor | |
| AU2011302344B2 (en) | HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients | |
| WO2008116053A3 (en) | Fap-activated chemotherapeutic compounds, and methods of use thereof | |
| US20130150385A1 (en) | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor | |
| US20140255348A1 (en) | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors | |
| EP2663305A1 (en) | Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors | |
| US20140315943A1 (en) | Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors | |
| JP2013537229A5 (enExample) | ||
| EP2714039A1 (en) | Combination therapy of hsp90 inhibitory compounds with mek inhibitors | |
| JP2011517457A5 (enExample) | ||
| WO2013067165A1 (en) | Combination therapy of hsp90 inhibitors with platinum-containing agents | |
| WO2012162584A1 (en) | Combination therapy of hsp90 inhibitory compounds with chk inhibitors | |
| JP2014507443A5 (enExample) | ||
| JP2009513662A5 (enExample) | ||
| MX2010004176A (es) | Derivado de triazol 1,3,5-trisustituido. | |
| EP2678013A1 (en) | Combination therapy of hsp90 inhibitory compounds with radiotherapy | |
| JP2010524937A5 (enExample) | ||
| MX2017010299A (es) | Terapia de combinacion de inhibidores de la proteina de choque termico 90 (hsp90) e inhibidores de muerte programada 1(pd-1) para tratar cancer. | |
| JP2015531373A5 (enExample) | ||
| Çıkla-Süzgün et al. | Recent progress on apoptotic activity of triazoles | |
| WO2005039550A3 (en) | Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds | |
| EP3866805A1 (en) | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |